L-DOPA-induced dyskinesia, is striatal dopamine depletion a requisite?

Journal of the Neurological Sciences
Philippe Huot

Abstract

l-3,4-Dihydroxyphenylalanine (L-DOPA) is currently the most effective drug available to treat the symptoms of Parkinson's disease (PD). A limitation is that chronic administration of L-DOPA almost invariably, but not universally, leads to the development of abnormal involuntary movements, dyskinesia. Research suggests that striatal dopamine depletion is an important aetiological factor leading to dyskinesia development. However, in studies where L-DOPA was administered to normal animals and human subjects not afflicted by PD, abnormal involuntary movements were sometimes elicited. These studies are reviewed here and their potential significance for the pathophysiology of dyskinesia is discussed. It is concluded that, if striatal dopamine depletion may not be a requisite for the development of dyskinesia, it probably acts as a permissive factor, at least with the doses commonly employed in the clinic.

References

Oct 1, 1976·Journal of Neurology, Neurosurgery, and Psychiatry·C LoebC Albano
Aug 23, 1986·Lancet·C von Scheele
Jan 1, 1987·European Neurology·M A BédardR Godbout
Jan 1, 1986·Movement Disorders : Official Journal of the Movement Disorder Society·N QuinnC D Marsden
Jan 1, 1987·Clinical Neuropharmacology·S Akpinar
Aug 1, 1987·The International Journal of Neuroscience·R SandykC R Bamford
Jun 22, 1972·The New England Journal of Medicine·H L KlawansA Barbeau
Nov 1, 1972·Neurology·A N LiebermanM Goldstein
Dec 1, 1971·Journal of Neurology, Neurosurgery, and Psychiatry·R J MonesG J Siegel
Jan 1, 1970·The New England Journal of Medicine·I MenaG C Cotzias
Feb 16, 1967·The New England Journal of Medicine·G C CotziasL M Schiffer
Mar 1, 1971·Clinical Pharmacology and Therapeutics·C H Markham
May 8, 1980·The New England Journal of Medicine·H L KlawansA Barbeau
Jan 1, 1980·Annual Review of Pharmacology and Toxicology·E D Bird
Nov 1, 1982·Archives of Neurology·S Akpinar
Aug 1, 1996·The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques·P J BlanchetP J Bédard
Sep 26, 1997·Movement Disorders : Official Journal of the Movement Disorder Society·A H RajputR Macaulay
Jun 1, 2000·Movement Disorders : Official Journal of the Movement Disorder Society·D A Di MonteW J Langston
Oct 10, 2003·Movement Disorders : Official Journal of the Movement Disorder Society·Claudia TrenkwalderRalf Kohnen
Oct 30, 2004·Annals of Neurology·Incarnation AubertErwan Bezard
Nov 20, 2004·Movement Disorders : Official Journal of the Movement Disorder Society·Mariese A HelyRobert Trafficante
Dec 5, 2006·Brain : a Journal of Neurology·Philippe HuotAndré Parent
Mar 14, 2007·Neurobiology of Disease·Céline GuigoniErwan Bezard
Apr 3, 2008·The Annals of Pharmacotherapy·Ogochukwu Chidozie Molokwu
Dec 6, 2008·Movement Disorders : Official Journal of the Movement Disorder Society·Robert A HauserUNKNOWN FIRST-STEP Study Group
Nov 12, 2010·Movement Disorders : Official Journal of the Movement Disorder Society·Claire L TomlinsonCarl E Clarke

❮ Previous
Next ❯

Citations

Jul 4, 2020·Critical Reviews in Food Science and Nutrition·Mauricio Restrepo-GallegoPatrícia H C Rondó
May 13, 2020·The European Journal of Neuroscience·Ivan Castela, Ledia F Hernandez
Oct 28, 2017·European Journal of Nuclear Medicine and Molecular Imaging·Han Soo YooPhil Hyu Lee

❮ Previous
Next ❯

Related Concepts

Related Feeds

Amyloid Lateral Sclerosis

Amyotrophic Lateral Sclerosis (ALS) is a progressive nervous system disease associated with the death of neurons that control voluntary muscles. Discover the latest research on ALS here.